Publications by Professor John Lunec - ePrints

Browsing publications by Professor John Lunec.

Newcastle Authors	Title	Year
Dr Hayden Bell Dr Helen Blair Samantha Jepson Gosling Dr Martin Galler Dan Astley et al.	Combination p53 activation and BCL-x_L/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia	2024
Dr Celine Cano Professor Jane Endicott Dr Ian Hardcastle Dr Claire Jennings Suzanne Kyle et al.	Discovery of ASTX295, a potent, next-generation small molecule antagonist of MDM2 with differentiated pharmacokinetic profile	2024
Maryam Zanjirband Zanjirband Professor Nicola Curtin Professor John Lunec	Erratum: Correction: Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer (Oncotarget (2017) 8 41 (69779-69796))	2024
Erhan Aptullahoglu Dr Sirintra Nakjang Dr Jonathan Wallis Dr Helen Marr Dr Scott Marshall et al.	RNA Sequencing Reveals Candidate Genes and Pathways Associated with Resistance to MDM2 Antagonist Idasanutlin in TP53 Wild-Type Chronic Lymphocytic Leukemia	2024
Dr Elaine Willmore Suzanne Kyle Dr Yan Zhao Huw Thomas Dr Kenneth Rankin et al.	Targeting the MDM2-p53 interaction: Time- and concentration-dependent studies in tumor and normal human bone marrow cells reveal strategies for an enhanced therapeutic index	2024
Erhan Aptullahoglu Dr Jonathan Wallis Dr Helen Marr Dr Elaine Willmore Professor John Lunec et al.	SF3B1 Mutations Are Associated with Resistance to Non-Genotoxic MDM2 Inhibition in Chronic Lymphocytic Leukemia	2023
Bassier Zadran Daniel Wainwright Dr Yvonne Bury Dr Saimir Luli Rachel Howarth et al.	Impact of retrotransposon protein L1 ORF1p expression on oncogenic pathways in hepatocellular carcinoma: the role of cytoplasmic PIN1 upregulation	2023
Dr Carmela Ciardullo Dr Jonathan Wallis Dr Helen Marr Dr Nicholas Bown Dr Elaine Willmore et al.	Splicing Modulation Results in Aberrant Isoforms and Protein Products of p53 Pathway Genes and the Sensitization of B Cells to Non-Genotoxic MDM2 Inhibition	2023
Dr Hayden Bell Dr Helen Blair Mankaran Singh Professor Anthony Moorman Professor Olaf Heidenreich et al.	Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia	2023
Professor John Lunec	p53 as a biomarker and potential target in gastrointestinal stromal tumors	2022
Victoria Chamberlain Dr Yvette Drew Professor John Lunec	Tipping growth inhibition into apoptosis by combining treatment with MDM2 and WIP1 inhibitors in p53^WT uterine leiomyosarcoma	2022
Dr Corey Chan Dr Emma Haagensen Dr Hayeit Tensaout Dr Kate Rennie Dr Zakareya Gamie et al.	Co‑localisation of intra‑nuclear membrane type‑1 matrix metalloproteinase and hypoxia inducible factor‑2α in osteosarcoma and prostate carcinoma cells	2021
Dr Praveen Dhondurao Sudhindar Daniel Wainwright Dr Santu Saha Rachel Howarth Misti McCain et al.	HCV Activates Somatic L1 Retrotransposition—A Potential Hepatocarcinogenesis Pathway	2021
Marco Zaki Dr Ahmed Mahdi Dr Gillian Patman Anna Whitehead Joao Mauricio et al.	Key features of the environment promoting liver cancer in the absence of cirrhosis	2021
Dr Ian Hardcastle Dr Ruth Bawn Dr Tim Blackburn Dr Celine Cano Dr Sarah Cully et al.	Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein–Protein Interaction	2021
Professor John Lunec	WIP1 inhibition by GSK2830371 potentiates HDM201 through enhanced p53 phosphorylation and activation in liver adenocarcinoma cells	2021
Dr Nicholas Bown Professor John Lunec Professor Deborah Tweddle	Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group	2020
Professor John Lunec	Pattern of nucleotide variants of TP53 and their correlation with the expression of p53 and its downstream proteins in a Sri Lankan cohort of breast and colorectal cancer patients	2020
Professor John Lunec	Targeting P53 as a future strategy to overcome gemcitabine resistance in biliary tract cancers	2020
Dr Chiao-En Wu Tsin Koay Professor Penny Lovat Professor John Lunec	TP53 mutant cell lines selected for resistance to MDM2 inhibitors retain growth inhibition by MAPK pathway inhibitors but a reduced apoptotic response	2019
Dr Chiao-En Wu Tsin Koay Arman Esfandiari Professor Penny Lovat Professor John Lunec et al.	ATM Dependent DUSP6 Modulation of p53 Involved in Synergistic Targeting of MAPK and p53 Pathways with Trametinib and MDM2 Inhibitors in Cutaneous Melanoma	2019
Dr Carmela Ciardullo Erhan Aptullahoglu Dr Laura Woodhouse Dr Wei-Yu Lin Dr Jonathan Wallis et al.	Non-genotoxic MDM2 inhibition selectively induces pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells	2019
Vahinipriya Manoharan Professor John Lunec	Nucleotide variants and protein expression of TP53 in a Sri Lankan cohort of patients with head and neck cancer	2019
Dr Lindi Chen Philip Berry Dr Jennifer Bonner Calum Kirk Dr Katrina Wood et al.	Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma	2019
Dr Yan Zhao Professor John Lunec	A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage	2018
Honorine Lebraud Dr Richard Noble Nicole Phillips Dr Yan Zhao Professor Herbie Newell et al.	A highly potent clickable probe for cellular imaging of MDM2 and assessing dynamic responses to MDM2-p53 inhibition	2018
Dr Lindi Chen Arman Esfandiari Professor John Lunec Professor Deborah Tweddle	Characterisation of the p53 pathway in cell lines established from TH-MYCN transgenic mouse tumours	2018
Lucy Gentles Liz Matheson Dr Nicholas Bown Alice Bradbury Maryam Zanjirband Zanjirband et al.	Characterization and drug sensitivity of a novel human overian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor	2018
Abdullah Malik Dr Jeffry Hogg Professor John Lunec Professor Derek Manas Jeremy French et al.	External validation of nomograms for prediction of survival outcome in retroperitoneal sarcoma using the North East England cohort	2018
Arman Esfandiari Nan Wang Dr Ahmed Mahdi Erhan Aptullahoglu Professor Penny Lovat et al.	Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeuticstrategy in cutaneous melanoma	2018
Maryam Zanjirband Zanjirband Professor Nicola Curtin Professor John Lunec	Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer	2017
Dr Aiste McCormick Gavin Cuthbert Dr Rachel O'Donnell Dr Brian Wilson Huw Thomas et al.	Functional characterisation of a novel ovarian cancer cell line, NUOC-1	2017
Dr Lindi Chen Philip Berry Dr Jennifer Bonner Dr Katrina Wood Professor Gareth Veal et al.	In vivo evaluation of the intravenous MDM2-p53 antagonist RO6839921 alone and in combination with temozolomide in TP53 wild-type orthotopic models of neuroblastoma	2017
Dr Catherine Drummond Arman Esfandiari Dr Xiaohong Lu Dr Claire Hutton Dr Jennifer Jackson et al.	TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation	2016
Arman Esfandiari Dr Sirintra Nakjang Professor John Lunec	Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner	2016
Dr Ioannis Kotsopoulos Dr Asima Mukhopadhyay Professor John Lunec Professor Nicola Curtin Ali Kucukmetin et al.	IN VITRO SINGLE AGENT RUCAPARIB CYTOTOXICITY AND CISPLATIN CHEMO-POTENTIATION IN CERVICAL CANCER CELL LINES	2016
Dr Ian Logan Dr Urszula McClurg Dr Dominic Jones Daniel O'Neill Dr Fadhel Shaheen et al.	Nutlin-3 inhibits androgen receptor-driven c-FLIP expression, resulting in apoptosis of prostate cancer cells	2016
Dr Ioannis Kotsopoulos Ali Kucukmetin Dr Asima Mukhopadhyay Professor John Lunec Professor Nicola Curtin et al.	Poly(ADP-Ribose) Polymerase in Cervical Cancer Pathogenesis Mechanism and Potential Role for PARP Inhibitors	2016
Maryam Zanjirband Zanjirband Professor Richard Edmondson Professor John Lunec	Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents in combined treatment with cisplatin in ovarian cancer	2016
Dr Jeffry Hogg Professor Derek Manas Dr Daniela Lee Dr Petra Dildey Professor John Lunec et al.	Surgical outcome and patterns of recurrence for retroperitoneal sarcoma at a single centre.	2016
Dr Laura Woodhouse Clark Crawford Dr Scott Marshall Dr Nicholas Bown Dr Elaine Willmore et al.	Assessment and targeting of the MDM2-p53 network in CLL	2015
Dr Arman Esfandiari Professor Nicola Curtin Professor John Lunec	Chemical inhibition or transient knockdown of wild-type p53 induced phosphatase 1 (WIP1/PPM1D) potentiates the response to MDM2 inhibitors in a p53-dependent manner	2015
Dr Nicholas Bown Professor John Lunec Professor Deborah Tweddle	Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification	2015
Dr Ashleigh Herriott Dr Susan Tudhope Gesa Junge Natalie Rodrigues Dr Miranda Patterson et al.	PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in Chronic Lymphocytic Leukaemia	2015
Professor Ruth Plummer Dr Jane Margetts Professor John Lunec Dr Joyce Nutt	Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNA as a Potential Biomarker	2015
Dr Lindi Chen Professor Herbie Newell Professor John Lunec Professor Deborah Tweddle	Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma	2015
Dr Andrey Zaytsev Dr Barry Dodd Emeritus Professor Bernard Golding Professor Roger Griffin Dr Xiaohong Lu et al.	Searching for Dual Inhibitors of the MDM2-p53 and MDMX-p53 Protein-Protein Interaction by a Scaffold-Hopping Approach	2015
Alex Liu Dr Catherine Drummond Professor Jane Endicott Emeritus Professor Bernard Golding Professor Roger Griffin et al.	An X-ray crystal structure-based understanding of the inhibition of the MDM2-p53 protein-protein interaction by isoindolinones	2014
Dr Emma Bell Dr Frida Ponthan Claire Whitworth Professor Deborah Tweddle Professor John Lunec et al.	COX2 expression in neuroblastoma increases tumorigenicity but does not affect cell death in response to the COX2 inhibitor celecoxib	2014
Dr Jeffry Hogg Jeremy French Professor John Lunec	Nutlin-3 is cytotoxic in TP53 WT liposarcoma and leiomyosarcoma in vitro and can act both synergistically and antagonistically with ionising radiation	2014
Dr Susan Tudhope Dr Yan Zhao Dr Anita Wittner Annalisa Bertoli Santosh Adhikari et al.	Profiling inhibitors of MDM2: p53 and MDMX: p53 in relation to MDMX protein levels	2014
Dr Lindi Chen Dr Yan Zhao Dr Gail Halliday Philip Berry Professor Herbie Newell et al.	Structurally diverse MDM2-p53 antagonists act as modulators of MDR-1 function in neuroblastoma	2014
Professor John Lunec	The clinical development of p53-reactivating drugs in sarcomas - charting future therapeutic approaches and understanding the clinical molecular toxicology of Nutlins	2014
Annalisa Bertoli Santosh Adhikari Dr Suzannah Harnor Dr Yan Zhao Professor John Lunec et al.	Validation studies with small-molecule modulators of the MDM2/MDMX-p53 binding interaction	2014
Dr Tim Blackburn Christopher Coxon Dr Xiaohong Lu Emeritus Professor Bernard Golding Professor Roger Griffin et al.	Diaryl- and triaryl-pyrrole derivatives: inhibitors of the MDM2-p53 and MDMX-p53 protein-protein interactions	2013
Nidal Boulos Dr Michael Tilby Professor Deborah Tweddle Professor John Lunec	Identification and characterisation of STMN4 and ROBO2 gene involvement in neuroblastoma cell differentiation	2013
Sarah Cully Dr Celine Cano Emeritus Professor Bernard Golding Professor Roger Griffin Professor John Lunec et al.	Regiospecific synthesis of isoindolinones as MDM2 inhibitors	2013
Professor Deborah Tweddle Professor John Lunec	MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63	2012
Dr Swethajit Biswas Professor John Lunec Professor Kim Bartlett	Non-glucose metabolism in cancer cells—is it all in the fat?	2012
Dr Kenneth Rankin Professor John Lunec Craig Gerrand Dr Swethajit Biswas	Of Dogs and Men: Comparative Biology as a Tool for the Discovery of Novel Biomarkers and Drug Development Targets in osteosarcoma	2012
Dr Christine Challen Dr John Anderson Professor Zofia Chrzanowska-Lightowlers Professor Robert Lightowlers Professor John Lunec et al.	Recombinant human MDM2 oncoprotein shows sequence composition selectivity for binding to both RNA and DNA	2012
Dr Swethajit Biswas Dr Kenneth Rankin Anna Long Dr Jennifer Jackson Dr Mark Birch et al.	The prognostic role of MT1-MMP and HIF Isoforms in Human Osteosarcoma	2012
Dr Nicholas Bown Professor John Lunec Professor Deborah Tweddle	A Multilocus Technique for Risk Evaluation of Patients with Neuroblastoma	2011
Dr Ian Hardcastle Alex Liu Dr Eric Valeur Anna Watson Shafiq Ahmed et al.	Isoindolinone Inhibitors of the Murine Double Minute 2 (MDM2)-p53 Protein-Protein Interaction: Structure-Activity Studies Leading to Improved Potency	2011
Dr Karim Bennaceur Dr Catherine Drummond Professor Jane Endicott Emeritus Professor Bernard Golding Professor Roger Griffin et al.	MDM2-p53 protein-protein interaction inhibitors: A-ring substituted isoindolinones	2011
Dr Jane Carr-Wilkinson Bojidar Goranov Dr Chris Redfern Dr Laura Gamble Professor John Lunec et al.	Outcome of the p53-mediated DNA damage response in neuroblastoma is determined by morphological subtype and MYCN expression	2011
Dr Joyce Nutt Kieran O'Toole Dr Fiona Black Mike Cole Professor Ruth Plummer et al.	Expression of methylthioadenosine phosphorylase (MTAP) in malignant pleural mesothelioma (MPM) and its implication for pemetrexed-based chemotherapy	2010
Dr Jane Carr-Wilkinson Kieran O'Toole Angela Baker Julian Board Mike Cole et al.	High frequency of p53/MDM2/p14^ARFpathway abnormalities in relapsed neuroblastoma	2010
Dr Emma Bell Dr Lindi Chen Professor John Lunec Professor Deborah Tweddle	MYCN oncoprotein targets and their therapeutic potential	2010
Dr Lindi Chen Dr Laura Gamble Professor John Lunec Professor Deborah Tweddle	p53 is a direct transcriptional target of MYCN in neuroblastoma	2010
Dr Joyce Nutt Kieran O'Toole Dr Fiona Black Amy Quinn Professor Alan Calvert et al.	The role of folate receptor alpha (FR alpha) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy	2010
Amy Quinn Professor Alan Calvert Professor John Lunec	A Monoclonal Antibody for Detection of Folylpolyglutamate Synthetase in Paraffin Embedded Tissues	2009
Dr Joyce Nutt Kieran O'Toole Dr Fiona Black Professor Ruth Plummer Professor Alan Calvert et al.	Expression of folate receptor alpha (FRa) in malignant pleural mesothelioma patients by immunohistochemistry: a clinico-pathological analysis	2009
Dr Joyce Nutt Kieran O'Toole Professor John Lunec	Growth inhibition by tyrosine kinase inhibitors in mesothelioma cell lines	2009
Dr Ian Logan Hesta McNeill Susan Cook Dr Xiaohong Lu Professor John Lunec et al.	Heat shock factor-1 modulates p53 activity in the transcriptional response to DNA damage	2009
Dr Joyce Nutt Professor John Lunec	The wide variation in response of mesothelioma cell lines to pemetrexed and lack of relationship to presence of folate receptor alpha (Fra)	2009
Dr Xiaohong Lu Professor John Lunec	Disruption of the MYC transcriptional function by a small-molecule antagonist of MYC/MAX dimerization	2008
Dr Katrina Wood Dr Michael Jackson Dr Maria Lastowska Dr Darroch Hall Dr Helen Imrie et al.	Histological profile of tumours from MYCN transgenic mice	2008
Dr Xiaomei Lu Alex Liu Dr Ian Hardcastle Professor Roger Griffin Emeritus Professor Bernard Golding et al.	MDM2 and MDMX status as a determinant of in vitro cellular sensitivity to MDM2 antagonists in human tumour cell lines	2008
Emeritus Professor Bernard Golding Professor Roger Griffin Dr Claire Hutton Professor John Lunec Professor Herbie Newell et al.	MEDI 147-Isoindolinone-based inhibitors of the MDM2-p53 protein-protein interaction	2008
Professor John Lunec	Molecular pathology and potential therapeutic targets in soft-tissue sarcoma	2008
Seamus Kelly Dr John Anderson Dr Brian Angus Dr Christine Challen Professor John Lunec et al.	The predictive value of p53 and p33ING1b in patients with Dukes'C colorectal cancer	2008
Professor Alan Calvert Professor John Lunec	A novel monoclonal antibody for detection of folate receptor alpha in paraffin-embedded tissues	2007
Dr Ian Logan Hesta McNeill Susan Cook Dr Xiaohong Lu Professor John Lunec et al.	Analysis of the MDM2 antagonist nutlin-3 in human prostate cancer cells	2007
Dr Emma Bell Professor John Lunec Professor Deborah Tweddle	Cell cycle regulation targets of MYCN identified by gene expression microarrays	2007
Dr John Anderson Professor Robert Lightowlers Professor John Lunec	DNA and RNA Binding of a Bacterially Expressed Human MDM2 Onco-protein	2007
Dr Joyce Nutt Kilian Mellon Professor John Lunec	hEGR1 is induced by EGF, inhibited by gefitinib in bladder cell lines and related to EGF receptor levels in bladder tumours	2007
Dr Jane Carr-Wilkinson Dr Nicholas Bown Marian Case Dr Andrew Hall Professor John Lunec et al.	High-resolution analysis of allelic imbalance in neuroblastoma cell lines by single nucleotide polymorphism arrays	2007
Dr John Anderson Dr Christine Challen Dr Stephen Crosier Professor John Lunec	MDM2 RNA binding is blocked by novel monoclonal antibody h-MDM2-F4-14	2007
Dr Lindi Chen Professor Archibald Malcolm Dr Katrina Wood Mike Cole Professor Andrew Pearson et al.	p53 is nuclear and functional in both undifferentiated and differentiated neuroblastoma	2007
Dr Jane Carr-Wilkinson Dr Emma Bell Professor Andrew Pearson Professor John Lunec Professor Deborah Tweddle et al.	Increased frequency of aberrations in the p53/MDM2/p14ARF pathway in neuroblastoma cell lines established at relapse	2006
Dr Ian Hardcastle Dr Shafiq Ahmed Helen Atkins Gillian Farnie Emeritus Professor Bernard Golding et al.	Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold	2006
Dr Emma Bell Dr Jane Carr-Wilkinson Dr Xiaohong Lu Professor Penny Lovat Professor John Lunec et al.	The role of MYCN in the failure of MYCN amplified neuroblastoma cell lines to G1 arrest after DNA damage	2006
Professor John Lunec	Characterisation of a novel p53 down-regulated promoter in intron 3 of the human MDM2 oncogene	2005
Philip Keegan Professor John Lunec Kilian Mellon	erbB receptor expression patterns in human bladder cancer	2005
Dr Ian Hardcastle Shafiq Ahmed Emeritus Professor Bernard Golding Professor Roger Griffin Dr Claire Hutton et al.	Inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold	2005
Stuart Kemp Dr Ian Hardcastle Dr Shafiq Ahmed Emeritus Professor Bernard Golding Professor Roger Griffin et al.	Isoindolinone based inhibitors of the MDM2-p53 protein-protein interaction	2005
Dr Ian Hardcastle Dr Shafiq Ahmed Professor Alan Calvert Professor Nicola Curtin Gillian Farnie et al.	Isoindolinone-based inhibitors of the MDM2-p53 protein-protein interaction	2005
Professor John Lunec Julian Board Professor Andrew Pearson	No evidence for correlation of DDX1 gene amplification with improved survival probability in patients with MYCN-amplified neuroblastomas [15]	2005
Dr Joyce Nutt Henry Lazarowicz Kilian Mellon Professor John Lunec	Gefitinib ('Iressa', ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2	2004
Helen Atkins Professor John Lunec	Genomic organisation of the human MDM2 oncogene and relationship to its alternatively spliced mRNAs	2004
Dr Xiaohong Lu Professor Herbie Newell Professor Andrew Pearson Professor John Lunec	Identification of MYCN transcriptional activity inhibitors yields compounds which preferentially inhibit the growth of neuroblastoma cells	2004
Nidal Boulos Professor Andrew Pearson Dr Michael Tilby Professor John Lunec	1p deleted neuroblastoma cells differentiate following chromosome 1 reintroduction	2003
Garrett Durkan Dr Joyce Nutt Colin Marsh Dr Mary Robinson Professor David Neal et al.	Alteration in urinary matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio predicts recurrence in nonmuscle-invasive bladder cancer	2003
Professor Deborah Tweddle Julian Board Professor Andrew Pearson Professor John Lunec	Development of a real-time polymerase chain reaction assay for prediction of the uptake of meta-[131I]iodobenzylguanidine by neuroblastoma tumors	2003
Professor John Lunec	Disruption of MYC transcriptional function in cell-based reporter gene assays by small-molecule antagonists of MYC/MAX dimerization	2003
Dr John Anderson Dr Stephen Crosier Dr Jyotsna Shrimankar Professor John Lunec Dr Brian Angus et al.	Downregulation of nuclear expression of the p33^ING1binhibitor of growth protein in invasive carcinoma of the breast	2003
Dr Debbie Scott Joanna Elsden Professor Andrew Pearson Professor John Lunec	Genes co-amplified with MYCN in neuroblastoma: Silent passengers or co-determinants of phenotype?	2003
Gillian Farnie Dr Saeed Ahmed Professor John Lunec	Inhibition of the MDM2-p53 interaction as a potential target in cancer therapy	2003
Dr Joyce Nutt Garrett Durkan Kilian Mellon Professor John Lunec	Matrix metalloproteinases (MMPs) in bladder cancer: The induction of MMP9 by epidermal growth factor and its detection in urine	2003
Dr Nicholas Bown Julie Freeman-Edward Professor John Lunec Dr Katia Mazzocco Steven O'Neill et al.	Quality assessment of genetic markers used for therapy stratification	2003
Dr Jane Carr-Wilkinson Julian Board Dr Katrina Wood Professor Andrew Pearson Professor John Lunec et al.	Selection for p53 mutant cells by chemotherapy in high-risk neuroblastoma	2003
Dr Xiaohong Lu Professor Andrew Pearson Professor John Lunec	The MYCN oncoprotein as a drug development target	2003
Dr Debbie Scott Julian Board Dr Xiaohong Lu Professor Andrew Pearson Dr Rebecca Kenyon et al.	The neuroblastoma amplified gene, NAG: Genomic structure and characterisation of the 7.3 kb transcript predominantly expressed in neuroblastoma	2003
Professor Deborah Tweddle Professor Andrew Pearson Professor John Lunec	The p53 pathway and its inactivation in neuroblastoma	2003
Dr John Anderson Professor John Lunec Dr Brian Angus	The role of the tumour suppressor p33ING1b in human neoplasia	2003
Dr Maria Lastowska Simon Cotterill Natalie Bown Professor John Lunec Professor Tom Strachan et al.	Breakpoint position on 17q identifies the most aggressive neuroblastoma tumors	2002
Dr Brian Angus Professor John Lunec Dr Stephen Crosier Andrew Lodge Dr John Anderson et al.	Comparative assessment expression of the inhibitor of growth 1 gene (ING1) in normal and neoplastic tissues	2002
Nidal Boulos Professor Andrew Pearson Dr Michael Tilby Professor John Lunec	Functional complementation analysis of chromosome 1 in neuroblastoma	2002
Professor John Lunec Professor Alan Calvert	Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism	2002
Dr John Anderson Dr Katrina Wood Professor John Lunec Dr Andrew Hall Dr Michael Reid et al.	Loss of nuclear expression of the p33ING1b inhibitor of growth protein in childhood acute lymphoblastic leukaemia	2002
Dr John Anderson Dr Marie Mathers Dr Niamh Leonard Dr Stephen Crosier Professor John Lunec et al.	Nuclear to cytoplasmic compartment shift of the p33ING1b tumour suppressor protein is associated with malignancy in melanocytic lesions	2002
Seamus Kelly Dr John Anderson Dr Brian Angus Professor John Lunec	p33/ING1 nuclear expression and TP53 gene mutation in colorectal cancer and their association with clinical outcome	2002
Dr John Anderson Dr Stephen Crosier Dr Jyotsna Shrimankar Professor John Lunec Dr Brian Angus et al.	p33^ING1b tumour suppressor immunohistochemical expression in invasive breast carcinomas	2002
Professor John Lunec Julian Board Professor Andrew Pearson	Quantification of MYCN, DDX1, and NAG gene copy number in neuroblastoma using a real-time quantitative PCR assay	2002
Alice Burns Dr Evelyn Jaros Mike Cole Emeritus Professor Robert Perry Professor Andrew Pearson et al.	The molecular pathology of p53 in primitive neuroectodermal tumours of the central nervous system	2002
Seamus Kelly Dr John Anderson Dr Brian Angus Professor John Lunec	TP53 and p33(Ing1) are co-determinants of prognosis in colorectal cancer	2002
Dr Xiaomei Lu Julie Errington Professor Nicola Curtin Professor John Lunec Professor Herbie Newell et al.	The impact of p53 status on cellular sensitivity to antifolate drugs	2001
Dr Richard Gilbertson Roberto Hernan Emeritus Professor Robert Perry Professor John Lunec Professor Andrew Pearson et al.	Clinical and molecular stratification of disease risk in medulloblastoma	2001
Dr Khaver Qureshi Thomas Griffiths Dr Mary Robinson Colin Marsh Dr James Roberts et al.	Combined p21WAF1/CIP1 and p53 overexpression predict improved survival in muscle-invasive bladder cancer treated by radical radiotherapy	2001
Dr Brian Angus Professor David Neal Professor John Lunec Kilian Mellon	Cyclin D1 expression in transitional cell carcinoma of the bladder: Correlation with p53, waf1, pRb and Ki67	2001
Professor Deborah Tweddle Professor Archibald Malcolm Dr Nicholas Bown Professor Andrew Pearson Professor John Lunec et al.	Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line	2001
Professor John Lunec Seamus Kelly Dr John Anderson Dr Brian Angus	Expression of p33/ING1 gene products in colorectal cancer and its correlation with survival	2001
Dr Debbie Scott Professor Andrew Pearson Professor John Lunec	Identification of novel coding exons within the neuroblastoma amplified gene, NAG.	2001
Professor Alan Calvert Professor Nicola Curtin Emeritus Professor Bernard Golding Professor Roger Griffin Dr Ian Hardcastle et al.	Inhibiting the MDM2-p53 interaction using low molecular weight compounds	2001
Joanna Elsden Dr Rebecca Kenyon Professor Andrew Pearson Professor John Lunec	Is DDX1 an oncogene? How does its pattern of expression relate to its amplification status?	2001
Dr Maria Lastowska Dr Nicholas Bown Professor John Lunec Professor Tom Strachan Professor Andrew Pearson et al.	Molecular cytogenetic definition of 17q translocation breakpoints in neuroblastoma	2001
Dr Maria Lastowska Dr Nicholas Bown Professor John Lunec Professor Tom Strachan Professor Andrew Pearson et al.	Molecular cytogenetic definition of 17q translocation breakpoints in neuroblastoma	2001
Dr Richard Gilbertson Roberto Hernan Professor David Ellison Emeritus Professor Robert Perry Professor Andrew Pearson et al.	Novel ErbB4 juxtamembrane splice variants and the truncated ErbB2 receptor isoform are frequently expressed in childhood medulloblastoma	2001
Dr Richard Gilbertson Roberto Hernan Professor David Ellison Emeritus Professor Robert Perry Professor Andrew Pearson et al.	Novel ERBB4 juxtamembrane splice variants are frequently expressed in childhood medulloblastoma	2001
Dr John Anderson Professor John Lunec Dr Andrew Hall Dr Michael Reid Dr Brian Angus et al.	p33(ING1b) tumour suppresser protein expression in childhood acute lymphoblastic leukaemia by immunohistochemistry	2001
Dr Stephen Crosier Dr John Anderson Dr Marie Mathers Dr Niamh Leonard Dr Stephen Crosier et al.	p33(ING1b) tumour suppresser protein expression in melanocytic lesions, an immunohistochemical study of 67 cases	2001
Seamus Kelly Professor John Lunec Dr John Anderson Dr Brian Angus	p33/ING1 nuclear expression in colorectal cancer and its correlation with metastasis and survival	2001
Dr John Anderson Dr Stephen Crosier Professor John Lunec Dr Brian Angus	p33^ING1b tumour suppresser protein expression in thyroid lesions determined by immunohistochemistry	2001
Professor Deborah Tweddle Professor Archibald Malcolm Mike Cole Professor Andrew Pearson Professor John Lunec et al.	p53 cellular localization and function in neuroblastoma: evidence for defective G1 arrest despite WAF1 induction in MYCN-amplified cells	2001
Garrett Durkan Dr Joyce Nutt Professor David Neal Professor John Lunec Kilian Mellon et al.	Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder	2001
Simon Cotterill Professor John Lunec Professor Andrew Pearson	Relationship between histopathological features, MYCN amplification, and prognosis: A UKCCSG study	2001
Dr Paul Jowsey Gillian Farnie Professor barbara Durkacz Professor John Lunec	The dependence of p63 induction and activity on poly (ADP-ribose) polymerase-1	2001
Professor Andrew Pearson Emeritus Professor Robert Perry Professor John Lunec	Detection of amplified and transcribed sequences at the chromosome 12q13-15 locus in NGP neuroblastoma cells by Alu-PCR	2000
Professor John Lunec Vanessa Ashton Jennifer Wilson	Expression of cyclin-dependent kinase inhibitor p21((WAF1)) and p53 tumour suppressor gene in laryngeal cancer	2000
Dr Nicholas Bown Professor John Lunec Professor Archibald Malcolm Professor Andrew Pearson	Fluorescence in situ hybridization techniques for the rapid detection of genetic prognostic factors in neuroblastoma	2000
Dr Brian Angus Professor John Lunec Dr John Anderson	Monoclonal antibodies raised to products of the ING1 tumour suppressor gene locus.	2000
Dr John Anderson Dr Brian Angus Professor John Lunec	Sequencing of ING1 tumour suppressor gene cDNAs generated from mRNA recovered from normal and neoplastic cell lines.	2000
Philip Keegan Professor John Matthews Professor John Lunec Professor David Neal	Statistical problems with 'optimal' thresholds in studies of new prognostic factors in urology	2000
Dr Brian Angus Dr Sathyarathna Gokul Professor Alan Calvert Professor John Lunec	Bcl-2 expression is a potential prognostic co-factor with P53- mutation status in epithelial ovarian carcinoma	1999
Dr Catherine Bladen Professor John Lunec	Can the acidic domain of the MDM2 oncoprotein act as a transcriptional transactivation domain?	1999
Professor Alan Calvert Dr Martin Highley Professor John Lunec Professor Alan Boddy	Carboplatin and paclitaxel, alone and in combination: Dose escalation, measurement of renal function, and role of the p53 tumor suppressor gene	1999
Dr Richard Gilbertson Roberto Hernan Professor Andrew Pearson Professor John Lunec	Expression and characterisation of novel ErbB-4 alternative spliced variants by childhood	1999
Gordon Taylor Professor John Lunec Professor Andrew Pearson Professor Herbie Newell	Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines	1999
Dr Joyce Nutt Garrett Durkan Professor John Lunec	Matrixmetalloproteinase stimulation in bladder tumour cell lines and elevated levels in the urine of bladder tumour patients.	1999
Philip Keegan Professor John Lunec Professor David Neal	p53 and p53-regulated genes in bladder cancer - Reply	1999
Philip Keegan Professor John Matthews Professor John Lunec Professor David Neal	Statistical problems with "optimal' cut-points in studies of new prognostic factors in urology.	1999
Dr Richard Gilbertson Roberto Hernan Professor Andrew Pearson Professor John Lunec	The ErbB2 receptor represents a potential target for novel therapies in childhood medulloblastoma.	1999
Dr Khaver Qureshi Thomas Griffiths Dr Mary Robinson Dr James Roberts Professor John Lunec et al.	TP53 accumulation predicts improved survival in patients resistant to systemic cisplatin-based chemotherapy for muscle-invasive bladder cancer	1999
Professor John Lunec	A novel p53 binding sequence in intron 3 of the human MDM2 proto-oncogene: A putative additional p53-dependent promoter	1998
Dr Christine Challen Thomas Griffiths Dr Mary Robinson Professor David Neal Professor John Lunec et al.	Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: High frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis	1998
Dr Khaver Qureshi Thomas Griffiths Dr Mary Robinson Reginald Hall Professor John Lunec et al.	Chemotherapy and muscle-invasive bladder cancer: Assessment of p53 immuno-reactivity (IR) as a predictor of response	1998
Dr Brian Angus Professor David Neal Professor John Lunec Kilian Mellon	Cyclin Dl expression in TCC of the bladder: Correlation with WAF1, p53 and Ki67	1998
Dr Catherine Bladen Professor John Lunec	Does the acidic domain of the MDM2 oncoprotein have a transcriptional control function?	1998
Professor Deborah Tweddle Professor Andrew Pearson Professor Archibald Malcolm Professor John Lunec	Does TP53 function in neuroblastoma?	1998
Dr Wendy Scaife Professor David Neal Professor John Lunec	Evaluation of the yeast functional (FASAY) assay for detecting p53 mutations in bladder cancers	1998
Professor John Lunec Emerita Professor Janet Wilson Dr Charles Kelly	Expression of cyclin dependent kinase inhibitors in laryngeal cancer	1998
Alice Burns Dr Evelyn Jaros Professor Andrew Pearson Emeritus Professor Robert Perry Professor John Lunec et al.	Expression of p53, Waf-1, Bcl-2, and Bax in central primitive neuroectodermal tumours (cPNET)	1998
Dr Richard Gilbertson Professor Steven Clifford Dr Christopher Wright Emeritus Professor Robert Perry Professor Andrew Pearson et al.	Expression of the ErbB-neuregulin signaling network during human cerebellar development: Implications for the biology of medulloblastoma	1998
Professor John Lunec	Genomic mapping of the human MDM2 oncogene and the relationship between exon/intron boundaries and variant MDM2 transcripts	1998
Dr Joyce Nutt Kilian Mellon Dr Khaver Qureshi Professor John Lunec	Matrix metalloproteinase-1 is induced by epidermal growth factor in human bladder tumour cell lines and is detectable in urine of patients with bladder tumours	1998
Dr Khaver Qureshi Professor John Lunec Professor David Neal	Molecular biological changes in bladder cancer	1998
Dr Maria Lastowska Dr Nicholas Bown Professor John Lunec Professor Tom Strachan Professor Andrew Pearson et al.	Molecular cytogenetic delineation of 17q translocation breakpoints in neuroblastoma cell lines	1998
Simon Cotterill Professor John Lunec Professor Andrew Pearson	Neuroblastoma cells provoke Schwann cell proliferation in vitro	1998
Philip Keegan Professor John Lunec Professor David Neal	p53 and p53-regulated genes in bladder cancer	1998
Dr Andrew Hall Professor John Lunec Professor Herbie Newell Professor Andrew Pearson Geoffrey Taylor et al.	Thymidylate synthase expression in nolatrexed and methotrexate-resistant human leukaemia cell lines	1998
Professor Deborah Tweddle Professor Archibald Malcolm Dr Michael Reid Mike Cole Professor John Lunec et al.	TP53 and related protein expression in primary and metastatic neuroblastoma	1998
Dr Rebecca Kenyon Professor Andrew Pearson Professor John Lunec	Analysis of candidate gene co-amplification with MYCN in neuroblastoma	1997
Dr Richard Gilbertson Dr Evelyn Jaros Emeritus Professor Robert Perry Professor John Lunec Professor Andrew Pearson et al.	Mitotic percentage index: A new prognostic factor for childhood medulloblastoma	1997
Dr Richard Gilbertson Emeritus Professor Robert Perry Professor Andrew Pearson Professor John Lunec	Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma	1997
Dr Richard Gilbertson Dr Evelyn Jaros Professor John Lunec Professor Andrew Pearson	The epidermal growth factor receptor (EGFR) family and childhood medulloblastoma	1997
Professor Alan Calvert Dr Andrew Hall Professor John Lunec Professor Herbie Newell Professor Andrew Pearson et al.	The relationship between intrinsic thymidylate synthase expression and sensitivity to THYMITAQ® in human leukaemia and colorectal carcinoma cell lines	1997
Professor Steven Clifford Professor David Neal Professor John Lunec	Alterations in expression of the multidrug resistance-associated protein (MRP) gene in high-grade transitional cell carcinoma of the bladder	1996
Professor Alan Calvert Dr John Anderson Professor David Neal Professor John Lunec	Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: Transforming ability and frequent detection in human cancer	1996
Kilian Mellon Professor John Lunec Dr Christopher Wright Professor David Neal	C-erbB-2 in bladder cancer: Molecular biology, correlation with epidermal growth factor receptors and prognostic value	1996
Professor Steven Clifford Professor David Neal Professor John Lunec	High level expression of the multidrug resistance (MDR1) gene in the normal bladder urothelium: A potential involvement in protection against carcinogens?	1996
Dr Joyce Nutt Professor John Lunec	Induction of metalloproteinase (MMP1) expression by epidermal growth factor (EGF) receptor stimulation and serum deprivation in human breast tumour cells	1996
Professor John Lunec	Interruption of binding of MDM-2 and p53 protein; potential for the treatment of cancer	1996
Dr Rebecca Kenyon Professor Archibald Malcolm Professor Andrew Pearson Professor John Lunec	Investigation of co-amplification of the candidate genes ornithine decarboxylase, ribonucleotide reductase, syndecan-1 and a DEAD box gene, DDX1, with N-myc in neuroblastoma	1996
Dr Evelyn Jaros Professor John Lunec	P53 overexpression in head and neck carcinoma and radiotherapy results	1996
Dr Evelyn Jaros Professor John Lunec	P53 overexpression in head and neck carcinoma and radiotherapy results	1996
Professor David Ellison Professor John Lunec Dr Evelyn Jaros	Accumulation of wild-type p53 in meningiomas	1995
Professor Alan Calvert Professor John Lunec	Molecular characterisation of 2 cell-lines selected for resistance to the folate-based thymidylate synthase inhibitor, ZD1694	1995
Professor John Lunec	A novel family of cathespin L-like (CTSLL) sequences on human-chromosome 10Q and related transcripts	1994
Professor John Lunec Carole Todd Professor Anthony Thody	Cultured Human Melanocytes Respond to MSH Peptides and ACTH	1994
Professor David Neal Professor John Lunec	FREQUENCY OF H-RAS MUTATIONS IN HUMAN BLADDER-CANCER DETECTED BY DIRECT SEQUENCING Frequency of H-ras mutations in human bladder cancer detected by direct sequencing	1994
Professor Steven Clifford David Thomas Professor David Neal Professor John Lunec	Increased MDR1 gene transcript levels in high-grade carcinoma of the bladder determined by quantitative PCR-based assay	1994
Professor John Lunec Professor Anthony Thody	MSH Receptors and Function in Amelanotic B16 Melanoma-Cells	1993
Dr Evelyn Jaros Professor John Lunec Emeritus Professor Robert Perry Professor Andrew Pearson	P53 Protein Overexpression Identifies a Group of Central Primitive Neuroectodermal Tumors with Poor Prognosis	1993
Professor John Lunec Dr Gajanan Sherbet	DNA Repair and Repair Fidelity in Metastatic Variants of the B16 Murine Melanoma	1993
Professor John Lunec	Analysis of the P54 tumor-suppressor gene in hepatocellular carcinomas from Britain	1992
Professor John Lunec Professor Anthony Thody	Demonstration of specific melanocyte stimulating hormone receptors on human melanocytes grown in a system free of artificial mitogens	1992
Professor barbara Durkacz Professor John Lunec Professor Michael Griffin	Murine Melanoma Cell-Differentiation and Melanogenesis Induced by Poly(ADP-Ribose) Polymerase Inhibitors	1992
Dr Christine Challen Professor John Lunec Professor Margaret Bassendine	Analysis of the p53 tumour suppressor gene in HCCs from Britain.	1992
Professor John Lunec Dr Christine Challen Dr Christopher Wright Professor David Neal	c-erbB-2 amplification and identical p53 mutations in concomitant transitional carcinomas of renal pelvis and urinary bladder	1992
Professor John Lunec Professor Alan Calvert	Human Lymphoblastoid-Cells with Acquired-Resistance to C²- Desamino-C²-Methyl-N¹⁰-Propargyl-5,8-Dideazafolic Acid - a Novel Folate-Based Thymidylate Synthase Inhibitor	1992
Professor John Lunec Professor Anthony Thody	MSH receptor expression and the relationship to melanogenesis and metastatic activity in B16 melanoma	1992
Professor John Lunec Professor Anthony Thody	The expression of functional MSH receptors on cultured human melanocytes	1992
Dr Christopher Wright Professor John Lunec Professor David Neal	P53, C-ERB-2 and EGFR in bladder cancer	1991
Dr Joyce Nutt Professor John Lunec	Phorbal ester and bryostatin effects on growth and the expression of estrogen and TGF-beta in breast-tumor cells	1991
Professor John Lunec Professor Margaret Bassendine	P53 - A frequent target for genetic abnormalities in human hetatocellular carcinomas (HCCS) in Britain	1991
Dr Joyce Nutt Professor John Lunec	Effects of estradiol, TPA and bryostatin on growth, the transcriptional regulation of estrogen responsive genes and the expression of TGF-beta in human breast tumor-lines	1990
Dr Joyce Nutt Professor John Lunec	Interactive effects of estradiol, TPA and bryostatin on growth and on the expression of estrogen responsive genes and TGF-beta in human breast tumor lines	1990
Professor John Lunec Dr Gajanan Sherbet Professor Anthony Thody	Alpha-melanocyte-stimulating hormone immunoreactivity in melanoma-cells	1990
Dr Gajanan Sherbet Professor John Lunec	DNA-Repair Fidelity and Recombination Proficiency in B16 Melanoma Metastatic Variants	1989
Professor John Lunec Dr Craig Parker Dr Gajanan Sherbet	Epidermal growth-factor receptor expression in primary breast-tumor tissue	1989
Professor John Lunec Dr Gajanan Sherbet Professor Anthony Thody	Pigment-cells are able to synthesize MSH peptides	1988
Professor John Lunec Dr Craig Parker Dr Gajanan Sherbet Professor Anthony Thody	Possible Autocrine Control of Growth and Progression of Melanonma by Alpha-MSH	1988
Professor John Lunec Dr Craig Parker Dr Gajanan Sherbet	The isolation of CDNA clones for cysteine proteases and measurement of the expression of corresponding genes in metastatic variants of B-16 melanoma	1988
Dr Gajanan Sherbet Dr Madurai Lakshmi Professor John Lunec Dr Craig Parker	The generation of metastatic mosaicism in B-16 murine melanoma	1987